- ISCI365 (Turkey): “Salicylate Market Size 2023 and Strategic Assessment – Among Top Players: A key leader in the pharmaceutical industry, Novacap acquired PCI Synthesis on June 20, 2018 to expand its offering in the US” (Feb. 27, 2023)
- Insider Media Limited: “Revenue climbs against challenging comparator at Dechra” (Feb. 27, 2023)
- FE InvestEgate: “Half-year Report – six months to 31 December 2022” (Feb. 27, 2023)
- Pharmaceutical Technology: “Seqens’ Boston R&D Centre, Devens, Massachusetts, USA Seqens has opened a $5m facility to develop and manufacture drugs and therapeutics in Devens, Massachusetts” (Feb. 23, 2023)
- Investment Reports/Newsweek: “Pierre Luzeau, CEO, Seqens” (Feb. 17, 2023)
- Market Up and Down: “Indian Clinical Trials Market Key Players: ICON PLC, PRA Health Inc., Syneos Health Inc., And SGS SA” (Feb. 16, 2023)
- A Greater Town: “India Clinical Trials Market Key Players: Clario, Cliantha Research, Cliniminds, And Clinirx” (Feb. 16, 2023)
- Daily Gram: “India Clinical Trials Market Key Players: Clario, Cliantha Research, Cliniminds, And Clinirx” (Feb. 16, 2023)
- Grand View Research: “India Clinical Trials Market Key Players: Clario, Cliantha Research, Cliniminds, And Clinirx” (Feb. 16, 2023)
- Chemical Weekly: “Seqens inaugurates flagship pharma R&D centre in US” (Feb. 14, 2023)
- Speciality Chemicals (via Twitter): “French CDMO Seqens has opened its $5 million ‘Seqens Boston R&D Center’ in Devens, Massachusetts, in place of an older one. https://buff.ly/3HEQu05” (Feb. 13, 2023)
- PharmaLive: “Key Trends in Biotech: Including More Consolidation and the Need to File INDs” (Feb. 13, 2023)
- ISCI365: “Analysis of Salicylate Market Size, Geography Trends and Leading Market Players” (Feb. 13, 2023)
- Chemical Weekly (via Twitter): “SEQENS inaugurates flagship pharma R&D centre in US #pharma #pharmaceuticals #excipients #lipids #…” (Feb. 10, 2023)
- Chemical Weekly (via LinkedIn): “SEQENS inaugurates flagship pharma R&D centre in US” (Feb. 10, 2023)
- ISPE Boston Blog: “Pharma Giant Seqens Opens New R&D Facility in Devens” (Feb. 10, 2023)
- MassBio: “Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston” (Feb. 9, 2023)
- ACS Publications: “Seqens opens a new research center (via C&EN)” (Feb. 6, 2023)
- Sharon Community TV: “Wise Friends: Caring for Your Aging Parent in Your Retirement Years” (Feb. 6, 2023)
- Sharon Community TV: “Wise Friends: Caring for Aging Parents with your Adult Siblings” (Feb. 6, 2023)
- Investidollar: “CEO Highlight: Pierre Luzeau on Seqens U.S. R&D Lab Funding – Contract Pharma” (Feb. 6, 2023)
- Contract Pharma: “CEO Spotlight: Pierre Luzeau on Seqens U.S. R&D Lab Investment Luzeau discusses expansion into U.S. markets, outsourcing trends, and the company’s plan for continued growth in the CDMO space” Feb. 6, 2023)
- Banker & Tradesman: “saw “Beacon Hill OKs New Frontiers for Devens Growth” (Feb. 5, 2023)
- Fitchburg Sentinel and Enterprise e-newsletter: “Pharmaceutical giant Seqens opens new research and development facility in Devens” (Feb. 4, 2023)
- Harvard Medical School Gazette (via Twitter): “A new study, led by researchers at HMS and @H_SeniorLife, found that age-related accumulation of abdominal fat is associated with lower muscle density” (Feb. 4, 2023)
- ReachMD: “Age-Related Fat May Impair Muscle Function” (Feb. 3, 2023)
- PublicNewsTime: “New study finds that age-related fat may lead to less effective muscle function” (Feb. 3, 2023)
- NewsBreak: “New Seqens lab joins growing biotech, pharmaceutical cluster at Devens” (Feb. 3, 2023)
- Harvard Medical School Gazette: “Age-Related Fat May Impair Muscle Function” (Feb. 3, 2023)
- C&EN: “Seqens opens a new research center near Boston” (Feb. 3, 2023)
- DCAT Value Chain Insights: “Supplier News: Eurapi, Seqens, Mikart and More: The latest from CDMOs, CMOs, and suppliers featuring Euroapi, Seqens, Mikart, Vector BioMed, Sanner and Jones Healthcare: Seqens Opens R&D Center” (Feb. 3, 2023)
- MSN: “Pharmaceutical giant Seqens opens new research and development facility in Devens” (Feb. 3, 2023)
- Nashoba Valley Voice: “Pharmaceutical giant Seqens opens new research and development facility in Devens” (Feb. 3, 2023)
- Lowell Sun: “Pharmaceutical giant Seqens opens new research and development facility in Devens” (Feb. 3, 2023)
- Fitchburg Sentinel & Enterprise (via Facebook): “Pharmaceutical giant Seqens opens new research and development facility in Devens” (Feb. 3, 2023)
- Fitchburg Sentinel & Enterprise: “Pharmaceutical giant Seqens opens new research and development facility in Devens” (Feb. 3, 2023)
- Fitchburg Sentinel & Enterprise e-newsletter: “Pharmaceutical giant Seqens opens new research and development facility in Devens” (Feb. 3, 2023)
- Harvard Press: “New Seqens lab joins growing biotech, pharmaceutical cluster at Devens” (Feb. 3, 2023)
- Devens Weekly News: “Seqens Group Opens Flagship Pharmaceutical R&D Center” (Feb. 3, 2023)
- EndPoints: “Manufacturing roundup: Ingredient manufacturer opens R&D center outside of Boston” (Feb. 2, 2023)
- Canton Citizen: “Residents of Orchard Cove continue challenging work” (Feb. 2, 2023)
- Speciality Chemicals Magazine: “Seqens opens Boston R&D centre” (Feb. 2, 2023)
- Trade & Industry Development: “MA: Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston” (Feb. 2, 2023)
- BioSpectrum Jobs: “Seqens plans to double the number of scientists by 2026 at its new facility” (Feb. 2, 2023)
- Pharma Industrial India: “Seqens opens flagship R&D centre in Greater Boston” (Feb. 2, 2023)
- King Street Properties: “Beacon Hill OKs New Frontiers for Devens Growth (via Banker & Tradesman)” (Feb. 2, 2023)
- Mass Life Sciences Center (via Twitter): “A great day for our ecosystem in Devens, MA. This week, @Seqens_CDMO opened its new, state-of-the-art, 15,000 sq. ft. R&D Center that will bring their customers advanced capabilities for the discovery and development of new drugs and therapeutics.” (Feb. 1, 2023)
- Mass Life Sciences Center (via Twitter): “According to the company, the $5 million investment ensures the facility will leverage the most advanced technologies, equipment and design while adhering to the highest quality, sustainability and safety levels. Seqens plans to double the number of scientists there by 2026.” (Feb. 1, 2023)
- Pharmaceutical Commerce: “Seqens Group Unveils R&D Center in Greater Boston” (Feb. 1, 2023)
- Outsourced Pharma: “Seqens Group Opens Flagship Pharmaceutical R&D Center In Greater Boston” (Feb. 1, 2023)
- Drug Development & Discovery: “Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston” (Feb. 1, 2023)
- Contract Pharma newsletter: “BREAKING NEWS: Seqens Opens Flagship R&D Center in Greater Boston Invests $5 million in a state-of-the-art, 15,000 sq.-ft. R&D center in Devens, MA” (Feb. 1, 2023)
- Big4Bio/Boston e-newsletter: “Seqens Group: Opens Flagship Pharmaceutical R&D Center in Greater Boston” (Feb. 1, 2023)
- Senator Jamie Eldridge (via Facebook): “It was wonderful to attend the ribbon-cutting of the expansion of the French pharmaceutical company Seqens Group’s R&D Center at Devens today! Seqens Group is a global leader in the development and manufacture of active pharmaceutical ingredients (APIs) and excipients including lipids used for the manufacture of RNA vaccines for COVID. Rep. Danillo A. Sena, Susan Coughlin Templeton of the office of Senator John Cronin (now representing part of Devens through Shirley!), and I were honored to join French Consul General Mustafa Soykurt in welcoming and congratulating Seqens CEO Pierre Luzeau on the expansion! It was a pleasure to tour the new facility on Buena Vista Street, where Seqens plans to double the number of scientists by 2026, and meet the impressive Seqens employees! As I noted in my remarks, Devens is an emerging biotech cluster, with Bristol Myers Squibb, King Street Properties’ Pathway Devens biomanufacturing facility, Avantor and the now-expanded Seqens R&D Center! Wonderful to see so many Devens and Nashoba Valley partners today, great way to end the first month of 2023!” (Feb. 1, 2023)
- State Representative Dan Sena (via Facebook): “I was glad to attend Seqens’ ribbon-cutting of their improved research and development laboratory today and present a House citation to their CEO Pierre Luzeau. Senator Jamie Eldridge, Susan Templeton from Senator John J. Cronin’s office and French Consul General Mustafa Soykurt were also present with us. Seqens is a leader in the manufacturing of active ingredients and pharmaceutical intermediates. The new facility in Devens improves Seqen’s capacity to develop and produce its products and services. It was great to celebrate this milestone, and I look forward to seeing their impact on the growth and development of Devens and the Commonwealth.” (Feb. 1, 2023)
- Mass Life Sciences Center (via Facebook): “A great day for our ecosystem in Devens, MA. This week, Seqens Group opened its new, state-of-the-art, 15,000 sq. ft. R&D Center that will bring their customers advanced capabilities for the discovery and development of new drugs and therapeutics.” (Feb. 1, 2023) According to the company, the $5 million investment ensures the new facility will leverage the most advanced technologies, equipment and design while adhering to the highest quality, sustainability and safety levels. Seqens plans to double the number of scientists there by 2026.
- The 495/MetroWest Partnership @495Partnership (via Twitter): “RT RepDanSenaMA: Great to attend Seqens’ ribbon-cutting of their improved R&D laboratory in Devens today and present a House citation to their CEO Pierre Luzeau. Senator Jamie Eldridge Susan Templeton from Sen. Cronin’s office and French Consul General Mustafa Soykurt were also present with us.” (Feb. 1, 2023)
- MedAdNews: “Key Trends in Biotech: Including More Consolidation and the Need to File INDs” (Feb. 2023)
